Last updated July 22, 2026
Key finding
38.6% risk difference for MASH resolution without worsening of fibrosis (95% CI 19.6-57.7, p < 0.001)
This study evaluated the effectiveness of tirzepatide in resolving metabolic dysfunction-associated steatohepatitis (MASH) without worsening fibrosis.
Quick read
The essential study design details in one scan.
EvidenceScore™
Moderate
Study type
RCTs
Follow-up
Extended (5–20+ y)
Risk of bias
High Risk
Save research, organize studies, and quickly find important evidence again.
Plain-language summary
A plain-language read of the study’s main message and where it applies.
Study focus
This study evaluated the effectiveness of tirzepatide in resolving metabolic dysfunction-associated steatohepatitis (MASH) without worsening fibrosis.
These findings are significant for clinicians treating patients with metabolic dysfunction-associated steatohepatitis, as effective treatment options are limited. The ability of tirzepatide to resolve MASH could lead to better management of liver health without exacerbating fibrosis, which is crucial for patient outcomes.
Statistical significance for fibrosis improvement was not reached in 59-79% of subgroups. The study's findings may not be generalizable to all populations due to specific inclusion criteria. Limited sample size may affect the robustness of the conclusions.
Published in
Publication details and source links for this paper.
Mark LH, Rohit L, Eric JL, et al. Tirzepatide for Resolution of Metabolic Dysfunction-Associated Steatohepatitis Without Worsening Fibrosis. JHEP Reports. 2025;7(8):101472. doi:10.1016/j.jhepr.2025.101472
Tirzepatide 5 mg showed a 38.6% risk difference for MASH resolution without worsening fibrosis (p < 0.001).
Tirzepatide 10 mg showed a 49.6% risk difference for MASH resolution without worsening fibrosis (p < 0.001).
Tirzepatide 15 mg showed a 60.1% risk difference for MASH resolution without worsening fibrosis (p < 0.001).
Evidence network
Understand where this research contributes within the broader evidence network.
This study contributes evidence to Tirzepatide and Fibrosis improvement without worsening of MASH, Resolution of Metabolic Dysfunction Associated Steatohepatitis (MASH).
This study contributes evidence to
Primary intervention
Tirzepatide
Primary outcomes
Evidence topics
Primary intervention
Intervention and outcome relationships this study adds to the evidence network.
Editorial context
See why this paper is useful beyond its individual results.
Evidence network role
This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.
1
Related topics
2
Evidence pairs
59
Related studies
Evidence topic
Contributes evidence
Save studies and evidence pages, organize your personal Evidence Tracker, and keep the research you care about in one place.
Primary evidence
Evidence topic
matched_intervention
Core evidence
The primary outcomes reported in this study.
Tirzepatide → Fibrosis improvement without worsening of MASH
Tirzepatide → Fibrosis improvement without worsening of MASH
Tirzepatide → Resolution of Metabolic Dysfunction Associated Steatohepatitis (MASH)
Tirzepatide → Resolution of Metabolic Dysfunction Associated Steatohepatitis (MASH)
Evidence Library
Save research, organize studies, and quickly find important evidence again.
Evidence Library
Save research, organize studies, and quickly find important evidence again.
Explore related studies, evidence collections, and research questions.
Relationships organized using the Dediabetes Evidence Intelligence™ framework.
This study contributes to evidence on GLP-1 Receptor Agonists and Fibrosis improvement without worsening of MASH, GLP-1 Receptor Agonists and Resolution of Metabolic Dysfunction Associated Steatohepatitis (MASH).
This study contributes to the evidence on the following intervention-outcome relationships.
Medications
Curated evidence collections and hubs this study is part of.
All studies measuring Fibrosis improvement without worsening of MASH
Measures Fibrosis improvement without worsening of MASH as a key outcome.
All studies on GLP-1 Receptor Agonists
Contributes to GLP-1 Receptor Agonists evidence base.
All studies measuring Resolution of Metabolic Dysfunction Associated Steatohepatitis (MASH)
Measures Resolution of Metabolic Dysfunction Associated Steatohepatitis (MASH) as a key outcome.
Latest published studies
Published within the last 2 years.
Jump to pre-filtered views in Evidence Explorer.
1 results
1 results
1 results
1 results
1 results
Generated from the study's connected evidence using Evidence Intelligence™.
Tirzepatide appears to improve Resolution of Metabolic Dysfunction Associated Steatohepatitis (MASH).
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
Resolution of Metabolic Dysfunction Associated Steatohepatitis (MASH)
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
Current evidence does not show a clear benefit of Tirzepatide for Fibrosis improvement without worsening of MASH.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
Fibrosis improvement without worsening of MASH
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | neutral | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
Next steps
Choose a next path through related evidence topics, Evidence Explorer views, and research summaries.
Open broader Evidence Explorer views for this relationship.
Read related research summaries.
Focused on evidence, not advertising.
Your data is always protected.
New studies added every day.
